ASCO GU 2020: Response Rates and Survival Remain Superior with Nivolumab Over Everolimus >5 Years in Advanced Renal Cell Carcinoma
Nivolumab monotherapy has shown persistent efficacy and safety.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.